3-(5-furan-2-yl-[1,2,4]oxadiazol-3-yl)-pyridine | 378776-36-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-(5-furan-2-yl-[1,2,4]oxadiazol-3-yl)-pyridine
• 英文别名: 5-(furan-2-yl)-3-pyridin-3-yl-1,2,4-oxadiazole
• CAS: 378776-36-4
• 化学式: C₁₁H₇N₃O₂
• mdl: MFCD00264596
• 分子量: 213.195
• InChiKey: WNMZRKCSRYCUFB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  65
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3-吡啶基偕胺肟 在 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 、 吡啶 为溶剂， 反应 2.0h， 以15%的产率得到3-(5-furan-2-yl-[1,2,4]oxadiazol-3-yl)-pyridine
  参考文献：
  名称：

  WO2008/28903

  摘要：

  公开号：

文献信息

• Compostions and Methods for Controlling Nematodes
  申请人：Williams Deryck J.

  公开号：US20090048311A1

  公开（公告）日：2009-02-19

  Compositions and processes for controlling nematodes are described herein, e.g., nematodes that infest plants or animals. The compounds include oxazoles, oxadiazoles and thiadiazoles.

  本文描述了用于控制线虫的组合物和过程，例如侵害植物或动物的线虫。这些化合物包括噁唑、噁二唑和噻二唑。
• [EN] COMPOSITIONS AND METHODS FOR IMPROVING AGRONOMIC CHARACTERISTICS OF PLANTS<br/>[FR] COMPOSITIONS ET PROCÉDÉS DESTINÉS À AMÉLIORER DES CARACTÉRISTIQUES AGRONOMIQUES DE PLANTES
  申请人：MONSANTO TECHNOLOGY LLC

  公开号：WO2016100766A1

  公开（公告）日：2016-06-23

  Compounds, compositions and methods for improving one or more agronomic characteristics of desired crop plants are described herein. The compounds include oxazoles, oxadiazoles and thiadiazoles.

  本文描述了改善所需作物植物一种或多种农艺特性的化合物、组合物和方法。这些化合物包括噁唑、噁二唑和噻二唑。
• Novel oxadiazole derivatives and their medical use
  申请人：Dahl Bjarne H.

  公开号：US20090312347A1

  公开（公告）日：2009-12-17

  This invention relates to novel oxadiazole derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

  本发明涉及一种新型的噁唑烷衍生物，其被发现是尼古丁乙酰胆碱受体的调节剂。由于其药理学特性，本发明中的化合物可能对治疗与中枢神经系统（CNS）的胆碱能系统、外周神经系统（PNS）、平滑肌收缩相关的疾病或疾患、内分泌疾病或疾患、神经退行性疾病或疾患、炎症、疼痛以及由于滥用化学物质而引起的戒断症状等疾病或疾患具有用处。
• NOVEL OXADIAZOLE DERIVATIVES AND THEIR MEDICAL USE
  申请人：DAHL Bjarne H.

  公开号：US20110294856A1

  公开（公告）日：2011-12-01

  This invention relates to novel oxadiazole derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

  本发明涉及一种新型的噁唑啉衍生物，其被发现是乙酰胆碱受体的调节剂。由于它们的药理特性，该发明中的化合物可能有用于治疗各种与中枢神经系统（CNS）的胆碱能系统、外周神经系统（PNS）、平滑肌收缩、内分泌疾病或紊乱、神经退行性疾病、炎症、疼痛以及由于滥用化学物质终止而引起的戒断症状相关的疾病或紊乱。
• PHARMACEUTICAL COMBINATIONS OF A NICOTINE RECEPTOR MODULATOR AND A COGNITIVE ENHANCER
  申请人：Olsen Gunnar M.

  公开号：US20100234349A1

  公开（公告）日：2010-09-16

  This invention relates to novel pharmaceutical compositions comprising therapeutically effective combination of a positive allosteric modulator of nicotine receptors; and a cognitive enhancer selected from the group consisting of a nicotine acetylcholine receptor agonist, an acetylcholine esterase inhibitor, a positive AMPA receptor modulator, an antipsychotic drug, an antidepressant drug and an anti Parkinson drug. The pharmaceutical compositions for use according to the invention are contemplated particularly useful for combating cognitive disorders.

  本发明涉及一种新型药物组合物，包括治疗有效的尼古丁受体正向变构调节剂和从以下组中选择的认知增强剂：尼古丁乙酰胆碱受体激动剂、乙酰胆碱酯酶抑制剂、正向AMPA受体调节剂、抗精神病药物、抗抑郁药物和抗帕金森药物。本发明的药物组合物特别适用于对抗认知障碍。